Opana ER 15mg: Uses, Formulation, and Safety Information

Opana ER 15mg is an extended-release prescription opioid medication that contains oxymorphone hydrochloride. It was historically prescribed for patients with moderate to severe, persistent pain requiring continuous opioid treatment over an extended period. Because oxymorphone can cause serious adverse effects, dependence, and potentially fatal overdose, treatment requires careful assessment and supervision by a qualified healthcare professional.

Opana ER 15mg: Active Ingredient and Medical Purpose

The active ingredient in Opana ER 15mg is oxymorphone hydrochloride, an opioid analgesic that acts on receptors in the central nervous system to change how the body perceives pain. The extended-release formulation was designed to provide medication release over time rather than serve as an immediate-relief option for occasional discomfort.

Opioid therapy is generally considered when other appropriate treatment options are inadequate. A prescriber evaluates the type of pain, medical history, previous treatments, and potential risks before determining whether an opioid is appropriate. This product information does not establish that a particular strength is suitable for an individual patient.

Opana ER 15mg: Understanding Extended-Release Tablets

Extended-release formulations differ from immediate-release medicines in how the active ingredient is released. These formulations should not be treated as interchangeable without professional guidance. The tablet strength alone does not determine an appropriate treatment plan, and switching between opioid products requires clinical assessment.

Extended-release opioid tablets must be handled according to their specific instructions. Crushing, chewing, breaking, or dissolving a tablet can release medication too quickly and lead to a life-threatening overdose. Never alter an opioid tablet or change its administration method without guidance from a qualified healthcare professional.

Opana ER 15mg: Prescribing and Medical Supervision

Oxymorphone treatment requires individualized evaluation. A prescriber considers previous opioid exposure, the severity of pain, other medicines, existing health conditions, and the possibility of adverse reactions. Patients should never use a product description as a basis for selecting a dose or starting opioid treatment.

Regular opioid use can lead to physical dependence. Stopping treatment suddenly may cause withdrawal symptoms, so any reduction or discontinuation should be discussed with the prescribing professional. Do not increase a dose, change medication, or use tablets prescribed for another person.

Opana ER 15mg: Side Effects and Important Risks

Possible side effects of oxymorphone include nausea, vomiting, constipation, dizziness, itching, drowsiness, and lightheadedness. These effects may interfere with balance, concentration, and everyday activities. Avoid driving or operating machinery when impaired.

More serious risks include respiratory depression, dangerously low blood pressure, addiction, misuse, and overdose. Risk can increase when opioids are combined with alcohol, benzodiazepines, sleeping medicines, or other central nervous system depressants. Do not combine these substances with opioid treatment unless a qualified professional has assessed the risks.

Seek emergency assistance if a person becomes unresponsive, is difficult to awaken, or develops slow, shallow, or stopped breathing. Naloxone can temporarily reverse an opioid overdose, but emergency medical care is still essential.

Opana ER 15mg: Precautions and Safe Storage

Before opioid treatment, patients should disclose breathing disorders, liver problems, gastrointestinal conditions, head injuries, pregnancy, and all medicines or supplements they use. Some conditions can increase the risk of serious complications.

Opioid medicines should be stored securely in their original packaging, away from children and other people. Accidental ingestion can be fatal. Follow pharmacist guidance for safe storage and disposal, and ask a healthcare professional whether naloxone should be available.

Opana ER 15mg: Product Status and Verification

The branded Opana ER product was voluntarily withdrawn from the U.S. market in 2017 and is listed as discontinued. The FDA determined that the product was not withdrawn for reasons of safety or effectiveness; this does not mean it is currently marketed or available. The status of generic oxymorphone extended-release products may differ and should be verified with a licensed pharmacist.

Medical disclaimer: This information is educational and does not replace official prescribing information, professional medical advice, or an individualized treatment plan.